Richard P Blye

USPTO Granted Patents = 11 (Patent Applications = 1)

CIPO Patents = 1

EPO Patents = 2 (Patent Applications = 3)

Average Co-Inventor Count = 3.8

ph-index = 4

Forward Citations = 109(Granted Patents)

Location History:

Bethesda, MD (US) (1990)
Highland, MD (US) (1996 - 2019)

Company Filing History:

9 out of 3,539

The United States of America, As Represented by the Secretary, Department of Health and Human Services

patents

1 out of 1,217

The United States of America As Represented by the Department of Health

patents

1 out of 832,843

Other

patents

Years Active: 1990-2019

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10351587 - Method of making and using 7α, 11β-dimethyl-17β-hydroxyestr-4-en-3-one 17-undecanoate (2019-07-16),

2. 8569276 - Structural modification of 19-norprogesterone I: 17-α-substituted-11-β-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents (2013-10-29),

3. 8003629 - 21-substituted progesterone derivatives as new antiprogestational agents (2011-08-23),

4. 7820642 - Nandrolone 17β-carbonates (2010-10-26),

5. 7759330 - 21-substituted progesterone derivatives as new antiprogestational agents (2010-07-20),

6. 7196074 - Methods of making, using and pharmaceutical formulations comprising 7α, 11β-dimethyl-17β-hydroxyestra-4, 14-dien-3-one and 17 esters thereof (2007-03-27),

7. 7087591 - 21-substituted progesterone derivatives as new antiprogestational agents (2006-08-08),

8. 6900193 - Structural modification of 19-norprogesterone I: 17-α-substituted-11-β-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents (2005-05-31),

9. 6861415 - 21-substituted progesterone derivatives as new antiprogestational agents (2005-03-01),

10. 5554603 - Orally active derivatives of 1,3,5(10)-estratriene (1996-09-10),

11. 4948790 - Long-acting androgenic compounds and pharmaceutical compositions thereof (1990-08-14),

Title: The Innovative Contributions of Richard P. Blye

Introduction

Richard P. Blye is a notable inventor based in Highland, MD (US), recognized for his significant contributions to the field of hormonal therapies. With a total of 11 patents to his name, Blye has made remarkable advancements in the development of compounds that have various medical applications.

Latest Patents

Blye's latest patents include innovative methods for making and using 7α, 11β-dimethyl-17β-hydroxyestr-4-en-3-one 17-undecanoate. These methods are crucial for various hormonal therapies, including dosage forms that comprise 7α, 11β-dimethyl-17β-hydroxy-4-estren-3-one bucyclate and 7α, 11β-dimethyl-17β-hydroxyestr-4-en-3-one 17-undecanoate. Additionally, he has developed structural modifications of 19-norprogesterone, focusing on 17-α-substituted-11-β-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents. These inventions are designed to address various medical conditions, including endometriosis, dysmenorrhea, and hormone-dependent tumors.

Career Highlights

Throughout his career, Blye has worked with prestigious organizations such as the National Institutes of Health, a component of the US Department of Health & Human Services, and the United States of America as represented by the Department of Health. His work has significantly impacted the field of hormonal therapies and has contributed to advancements in medical treatments.

Collaborations

Blye has collaborated with esteemed colleagues, including Hyun K. Kim and Pemmaraju Narasimha Rao. These partnerships have fostered innovation and have led to the development of groundbreaking medical solutions.

Conclusion

Richard P. Blye's contributions to the field of hormonal therapies through his patents and collaborations highlight his role as a significant inventor. His work continues to influence medical practices and improve patient outcomes.

This text is generated by artificial intelligence and may not be accurate.